Marije Leonie Groot Bruinderink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marije Leonie Groot Bruinderink has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Allard R. Feddes
University of Amsterdam
2 shared publications - Amy Matser
Nivel - Netherlands Institute for Health Services Research, Otterstraat 118, Utrecht, 3513 CR, The Netherlands, 31 629034652
2 shared publications Anders Boyd
Department of Infectious Diseases, Public Health Service Amsterdam, GGD Amsterdam, Nieuwe Achtergracht 100, 1018 WT, Amsterdam, The Netherlands
2 shared publications- Anders Boyd
Stichting HIV Monitoring Amsterdam The Netherlands
2 shared publications Elske Hoornenborg
Department of Infectious Diseases, Public Health Service Amsterdam, GGD Amsterdam, Nieuwe Achtergracht 100, 1018 WT, Amsterdam, The Netherlands
2 shared publications- Elske Hoornenborg
Amsterdam Institute for Immunology & Infectious Diseases (AI&I), Amsterdam, the Netherlands
2 shared publications
Latest Publications
- Open Access
- 13 April 2026
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 23 (1)
Representativeness of participants in a randomized controlled trial on modalities of monitoring oral HIV pre-exposure prophylaxis use
Background: We assessed whether participants in the EZI-PrEP study, a non-inferiority trial evaluating online and six-monthly monitoring of oral HIV pre-exposure prophylaxis (PrEP), represent the broader population of PrEP users in the Netherlands. Methods: We conducted a cross-sectional study using routinely collected data from September 2021 to August 2022 at four centres for sexual health (CSHs) in the Netherlands. Socio-demographic characteristics, sexual behaviour, and prevalence of bacterial STIs were compared between EZI-PrEP participants at baseline and other PrEP users during their first PrEP monitoring visit during the same period. Results: The analysis included 469 EZI-PrEP participants and 5161 other PrEP users, of whom 99% and 96% were men who have sex with men (MSM), respectively. EZI-PrEP participants were less often transgender or gender-divers persons (TGDP) (1% vs. 4%, p < 0.001), older (median age = 36 vs. 34 years, p = 0.004), more often born in the Netherlands (68% vs. 58%, p < 0.001), and more often completed a university/college degree (81% vs. 76%, p = 0.01). They also reported more group sex (38% vs. 33%, p = 0.023) and condomless anal sex (95% vs. 92%, p = 0.004), but less often sex work (1% vs. 6%, p < 0.001). Prevalence of bacterial STIs were no different between groups (19% vs. 18%, p = 0.77). Conclusions: The comparable STI prevalence suggests no difference in risk for HIV acquisition among EZI-PrEP participants and other PrEP users, making study outcomes applicable to a broader population of PrEP users. However, under-representation of TGDPs, sex workers, individuals not born in the Netherlands, and individuals without university or college degree may limit generalizability.
- 13 April 2026
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 23 (1)
Open AccessRepresentativeness of participants in a randomized controlled trial on modalities of monitoring oral HIV pre-exposure prophylaxis use
Background: We assessed whether participants in the EZI-PrEP study, a non-inferiority trial evaluating online and six-monthly monitoring of oral HIV pre-exposure prophylaxis (PrEP), represent the broader population of PrEP users in the Netherlands. Methods: We conducted a cross-sectional study using routinely collected data from September 2021 to August 2022 at four centres for sexual health (CSHs) in the Netherlands. Socio-demographic characteristics, sexual behaviour, and prevalence of bacterial STIs were compared between EZI-PrEP participants at baseline and other PrEP users during their first PrEP monitoring visit during the same period. Results: The analysis included 469 EZI-PrEP participants and 5161 other PrEP users, of whom 99% and 96% were men who have sex with men (MSM), respectively. EZI-PrEP participants were less often transgender or gender-divers persons (TGDP) (1% vs. 4%, p < 0.001), older (median age = 36 vs. 34 years, p = 0.004), more often born in the Netherlands (68% vs. 58%, p < 0.001), and more often completed a university/college degree (81% vs. 76%, p = 0.01). They also reported more group sex (38% vs. 33%, p = 0.023) and condomless anal sex (95% vs. 92%, p = 0.004), but less often sex work (1% vs. 6%, p < 0.001). Prevalence of bacterial STIs were no different between groups (19% vs. 18%, p = 0.77). Conclusions: The comparable STI prevalence suggests no difference in risk for HIV acquisition among EZI-PrEP participants and other PrEP users, making study outcomes applicable to a broader population of PrEP users. However, under-representation of TGDPs, sex workers, individuals not born in the Netherlands, and individuals without university or college degree may limit generalizability.
- Open Access
Representativeness of participants in a randomized controlled trial on modalities of monitoring oral HIV pre-exposure prophylaxis use
Background: We assessed whether participants in the EZI-PrEP study, a non-inferiority trial evaluating online and six-monthly monitoring of oral HIV pre-exposure prophylaxis (PrEP), represent the broader population of PrEP users in the Netherlands. Methods: We conducted a cross-sectional study using routinely collected data from September 2021 to August 2022 at four sexual health centres (SHCs) in the Netherlands. Socio-demographic characteristics, sexual behaviour, and prevalence of bacterial STIs were compared between EZI-PrEP participants at baseline and other PrEP users during their first PrEP monitoring visit in said time period. Results: The analysis included 469 EZI-PrEP participants and 5196 other PrEP users; respectively 99% and 96% were men who have sex with men (MSM). EZI-PrEP participants were less often transgender or gender divers persons (TGDP) (1% vs. 4%, p<0.001), older (median age=36 vs. 34 years, p=0.004), more often born in the Netherlands (68% vs. 58%, p<0.001), and more often completed a university/college degree (81% vs. 76%, p=0.01). They reported more group sex (38% vs. 33%, p=0.023) and condomless anal sex (95% vs. 92%, p=0.004), but less often sex work (1% vs. 6%, p<0.001). Prevalence of bacterial STIs was similar between groups (19% vs 18%, p=0.766). Conclusions: The similar STI prevalence suggests comparable risk for HIV acquisition among EZI-PrEP participants and other PrEP users, making EZI-PrEP study outcomes applicable to a broader population of PrEP users. However, under-representation of TGDPs, sex workers, individuals not born in the Netherlands, and individuals without university or college degree may limit generalizability.
Open AccessRepresentativeness of participants in a randomized controlled trial on modalities of monitoring oral HIV pre-exposure prophylaxis use
Background: We assessed whether participants in the EZI-PrEP study, a non-inferiority trial evaluating online and six-monthly monitoring of oral HIV pre-exposure prophylaxis (PrEP), represent the broader population of PrEP users in the Netherlands. Methods: We conducted a cross-sectional study using routinely collected data from September 2021 to August 2022 at four sexual health centres (SHCs) in the Netherlands. Socio-demographic characteristics, sexual behaviour, and prevalence of bacterial STIs were compared between EZI-PrEP participants at baseline and other PrEP users during their first PrEP monitoring visit in said time period. Results: The analysis included 469 EZI-PrEP participants and 5196 other PrEP users; respectively 99% and 96% were men who have sex with men (MSM). EZI-PrEP participants were less often transgender or gender divers persons (TGDP) (1% vs. 4%, p<0.001), older (median age=36 vs. 34 years, p=0.004), more often born in the Netherlands (68% vs. 58%, p<0.001), and more often completed a university/college degree (81% vs. 76%, p=0.01). They reported more group sex (38% vs. 33%, p=0.023) and condomless anal sex (95% vs. 92%, p=0.004), but less often sex work (1% vs. 6%, p<0.001). Prevalence of bacterial STIs was similar between groups (19% vs 18%, p=0.766). Conclusions: The similar STI prevalence suggests comparable risk for HIV acquisition among EZI-PrEP participants and other PrEP users, making EZI-PrEP study outcomes applicable to a broader population of PrEP users. However, under-representation of TGDPs, sex workers, individuals not born in the Netherlands, and individuals without university or college degree may limit generalizability.
- Open Access
- 8 November 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e51023
Online-Mediated HIV Pre-exposure Prophylaxis Care and Reduced Monitoring Frequency for Men Who Have Sex With Men: Protocol for a Randomized Controlled Noninferiority Trial (EZI-PrEP Study)
Background: Daily and event-driven HIV pre-exposure prophylaxis (PrEP) with oral tenofovir-emtricitabine is highly effective to prevent HIV in men who have sex with men (MSM). PrEP care generally consists of in-clinic monitoring every 3 months that includes PrEP dispensing, counseling, and screening for HIV and sexually transmitted infections (STIs). However, the optimal frequency for monitoring remains undetermined. Attending a clinic every 3 months for monitoring may be a barrier for PrEP. Online-mediated PrEP care and reduced frequency of monitoring may lower this barrier. Objective: The primary objective of this study is to establish the noninferiority of online PrEP care (vs in-clinic care) and monitoring every 6 months (vs every 3 months). The secondary objectives are to (1) examine differences between PrEP care modalities regarding incidences of STIs, HIV infection, and hepatitis C virus infection; retention in PrEP care; intracellular tenofovir-diphosphate concentration; and satisfaction, usability, and acceptability of PrEP care modalities; and (2) evaluate associations of these study outcomes with sociodemographic, behavioral, and psychological characteristics. Methods: This study is a 2×2 factorial, 4-arm, open-label, multi-center, randomized, controlled, noninferiority trial. The 4 arms are (1) in-clinic monitoring every 3 months, (2) in-clinic monitoring every 6 months, (3) online monitoring every 3 months, and (4) online monitoring every 6 months. The primary outcome is a condomless anal sex act with a casual partner not covered or insufficiently covered by PrEP (ie, “unprotected act”) as a proxy for HIV infection risk. Eligible individuals are MSM, and transgender and gender diverse people aged ≥18 years who are eligible for PrEP care at 1 of 4 participating sexual health centers in the Netherlands. The required sample size is 442 participants, and the planned observation time is 24 months. All study participants will receive access to a smartphone app, which contains a diary. Participants are requested to complete the diary on a daily basis during the first 18 months of participation. Participants will complete questionnaires at baseline and 6, 12, 18, and 24 months. Dried blood spots will be collected at 6 and 12 months for assessment of intracellular tenofovir-diphosphate concentration. Incidence rates of unprotected acts will be compared between the online and in-clinic arms, and between the 6-month and 3-month arms. Noninferiority will be concluded if the upper limit of the 2-sided 97.5% CI of the incidence rate ratio is <1.8. Results: The results of the main analysis are expected in 2024. Conclusions: This trial will demonstrate whether online PrEP care and monitoring every 6 months is noninferior to standard PrEP care in terms of PrEP adherence. If noninferiority is established, these modalities may lower barriers for initiating and continuing PrEP use and potentially reduce the systemic burden for PrEP providers. Trial Registration: ClinicalTrials.gov NCT05093036; https://tinyurl.com/28b8ndvj International Registered Report Identifier (IRRID): DERR1-10.2196/51023
- 8 November 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e51023
Open AccessOnline-Mediated HIV Pre-exposure Prophylaxis Care and Reduced Monitoring Frequency for Men Who Have Sex With Men: Protocol for a Randomized Controlled Noninferiority Trial (EZI-PrEP Study)
Background: Daily and event-driven HIV pre-exposure prophylaxis (PrEP) with oral tenofovir-emtricitabine is highly effective to prevent HIV in men who have sex with men (MSM). PrEP care generally consists of in-clinic monitoring every 3 months that includes PrEP dispensing, counseling, and screening for HIV and sexually transmitted infections (STIs). However, the optimal frequency for monitoring remains undetermined. Attending a clinic every 3 months for monitoring may be a barrier for PrEP. Online-mediated PrEP care and reduced frequency of monitoring may lower this barrier. Objective: The primary objective of this study is to establish the noninferiority of online PrEP care (vs in-clinic care) and monitoring every 6 months (vs every 3 months). The secondary objectives are to (1) examine differences between PrEP care modalities regarding incidences of STIs, HIV infection, and hepatitis C virus infection; retention in PrEP care; intracellular tenofovir-diphosphate concentration; and satisfaction, usability, and acceptability of PrEP care modalities; and (2) evaluate associations of these study outcomes with sociodemographic, behavioral, and psychological characteristics. Methods: This study is a 2×2 factorial, 4-arm, open-label, multi-center, randomized, controlled, noninferiority trial. The 4 arms are (1) in-clinic monitoring every 3 months, (2) in-clinic monitoring every 6 months, (3) online monitoring every 3 months, and (4) online monitoring every 6 months. The primary outcome is a condomless anal sex act with a casual partner not covered or insufficiently covered by PrEP (ie, “unprotected act”) as a proxy for HIV infection risk. Eligible individuals are MSM, and transgender and gender diverse people aged ≥18 years who are eligible for PrEP care at 1 of 4 participating sexual health centers in the Netherlands. The required sample size is 442 participants, and the planned observation time is 24 months. All study participants will receive access to a smartphone app, which contains a diary. Participants are requested to complete the diary on a daily basis during the first 18 months of participation. Participants will complete questionnaires at baseline and 6, 12, 18, and 24 months. Dried blood spots will be collected at 6 and 12 months for assessment of intracellular tenofovir-diphosphate concentration. Incidence rates of unprotected acts will be compared between the online and in-clinic arms, and between the 6-month and 3-month arms. Noninferiority will be concluded if the upper limit of the 2-sided 97.5% CI of the incidence rate ratio is <1.8. Results: The results of the main analysis are expected in 2024. Conclusions: This trial will demonstrate whether online PrEP care and monitoring every 6 months is noninferior to standard PrEP care in terms of PrEP adherence. If noninferiority is established, these modalities may lower barriers for initiating and continuing PrEP use and potentially reduce the systemic burden for PrEP providers. Trial Registration: ClinicalTrials.gov NCT05093036; https://tinyurl.com/28b8ndvj International Registered Report Identifier (IRRID): DERR1-10.2196/51023
- Open Access
- 20 July 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Online-Mediated HIV Pre-exposure Prophylaxis Care and Reduced Monitoring Frequency for Men Who Have Sex With Men: Protocol for a Randomized Controlled Noninferiority Trial (EZI-PrEP Study) (Preprint)
BACKGROUND Daily and event-driven HIV pre-exposure prophylaxis (PrEP) with oral tenofovir-emtricitabine is highly effective to prevent HIV in men who have sex with men (MSM). PrEP care generally consists of in-clinic monitoring every 3 months that includes PrEP dispensing, counseling, and screening for HIV and sexually transmitted infections (STIs). However, the optimal frequency for monitoring remains undetermined. Attending a clinic every 3 months for monitoring may be a barrier for PrEP. Online-mediated PrEP care and reduced frequency of monitoring may lower this barrier. OBJECTIVE The primary objective of this study is to establish the noninferiority of online PrEP care (vs in-clinic care) and monitoring every 6 months (vs every 3 months). The secondary objectives are to (1) examine differences between PrEP care modalities regarding incidences of STIs, HIV infection, and hepatitis C virus infection; retention in PrEP care; intracellular tenofovir-diphosphate concentration; and satisfaction, usability, and acceptability of PrEP care modalities; and (2) evaluate associations of these study outcomes with sociodemographic, behavioral, and psychological characteristics. METHODS This study is a 2×2 factorial, 4-arm, open-label, multi-center, randomized, controlled, noninferiority trial. The 4 arms are (1) in-clinic monitoring every 3 months, (2) in-clinic monitoring every 6 months, (3) online monitoring every 3 months, and (4) online monitoring every 6 months. The primary outcome is a condomless anal sex act with a casual partner not covered or insufficiently covered by PrEP (ie, “unprotected act”) as a proxy for HIV infection risk. Eligible individuals are MSM, and transgender and gender diverse people aged ≥18 years who are eligible for PrEP care at 1 of 4 participating sexual health centers in the Netherlands. The required sample size is 442 participants, and the planned observation time is 24 months. All study participants will receive access to a smartphone app, which contains a diary. Participants are requested to complete the diary on a daily basis during the first 18 months of participation. Participants will complete questionnaires at baseline and 6, 12, 18, and 24 months. Dried blood spots will be collected at 6 and 12 months for assessment of intracellular tenofovir-diphosphate concentration. Incidence rates of unprotected acts will be compared between the online and in-clinic arms, and between the 6-month and 3-month arms. Noninferiority will be concluded if the upper limit of the 2-sided 97.5% CI of the incidence rate ratio is <1.8. RESULTS The results of the main analysis are expected in 2024. CONCLUSIONS This trial will demonstrate whether online PrEP care and monitoring every 6 months is noninferior to standard PrEP care in terms of PrEP adherence. If noninferiority is established, these modalities may lower barriers for initiating and continuing PrEP use and potentially reduce the systemic burden for PrEP providers. CLINICALTRIAL ClinicalTrials.gov NCT05093036; https://tinyurl.com/28b8ndvj INTERNATIONAL REGISTERED REPORT DERR1-10.2196/51023
- 20 July 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessOnline-Mediated HIV Pre-exposure Prophylaxis Care and Reduced Monitoring Frequency for Men Who Have Sex With Men: Protocol for a Randomized Controlled Noninferiority Trial (EZI-PrEP Study) (Preprint)
BACKGROUND Daily and event-driven HIV pre-exposure prophylaxis (PrEP) with oral tenofovir-emtricitabine is highly effective to prevent HIV in men who have sex with men (MSM). PrEP care generally consists of in-clinic monitoring every 3 months that includes PrEP dispensing, counseling, and screening for HIV and sexually transmitted infections (STIs). However, the optimal frequency for monitoring remains undetermined. Attending a clinic every 3 months for monitoring may be a barrier for PrEP. Online-mediated PrEP care and reduced frequency of monitoring may lower this barrier. OBJECTIVE The primary objective of this study is to establish the noninferiority of online PrEP care (vs in-clinic care) and monitoring every 6 months (vs every 3 months). The secondary objectives are to (1) examine differences between PrEP care modalities regarding incidences of STIs, HIV infection, and hepatitis C virus infection; retention in PrEP care; intracellular tenofovir-diphosphate concentration; and satisfaction, usability, and acceptability of PrEP care modalities; and (2) evaluate associations of these study outcomes with sociodemographic, behavioral, and psychological characteristics. METHODS This study is a 2×2 factorial, 4-arm, open-label, multi-center, randomized, controlled, noninferiority trial. The 4 arms are (1) in-clinic monitoring every 3 months, (2) in-clinic monitoring every 6 months, (3) online monitoring every 3 months, and (4) online monitoring every 6 months. The primary outcome is a condomless anal sex act with a casual partner not covered or insufficiently covered by PrEP (ie, “unprotected act”) as a proxy for HIV infection risk. Eligible individuals are MSM, and transgender and gender diverse people aged ≥18 years who are eligible for PrEP care at 1 of 4 participating sexual health centers in the Netherlands. The required sample size is 442 participants, and the planned observation time is 24 months. All study participants will receive access to a smartphone app, which contains a diary. Participants are requested to complete the diary on a daily basis during the first 18 months of participation. Participants will complete questionnaires at baseline and 6, 12, 18, and 24 months. Dried blood spots will be collected at 6 and 12 months for assessment of intracellular tenofovir-diphosphate concentration. Incidence rates of unprotected acts will be compared between the online and in-clinic arms, and between the 6-month and 3-month arms. Noninferiority will be concluded if the upper limit of the 2-sided 97.5% CI of the incidence rate ratio is <1.8. RESULTS The results of the main analysis are expected in 2024. CONCLUSIONS This trial will demonstrate whether online PrEP care and monitoring every 6 months is noninferior to standard PrEP care in terms of PrEP adherence. If noninferiority is established, these modalities may lower barriers for initiating and continuing PrEP use and potentially reduce the systemic burden for PrEP providers. CLINICALTRIAL ClinicalTrials.gov NCT05093036; https://tinyurl.com/28b8ndvj INTERNATIONAL REGISTERED REPORT DERR1-10.2196/51023